Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.

Developing a vaccine that will stimulate broad HIV-specific T cell responses is difficult because of the variability in HIV T cell epitope sequences, which is in turn due to the high mutation rate and consequent strain diversity of HIV-1. We used a new Class II version of the EpiMatrix T cell epitope-mapping tool and Conservatrix to select highly conserved and promiscuous Class II HLA-restricted T cell epitopes from a database of 18,313 HIV-1 env sequences. Criteria for selection were: (1) number of HIV-1 strains represented as measured by Conservatrix; (2) EpiMatrix score; and (3) promiscuity (number of unique MHC motifs contained in the peptide). Using another vaccine design tool called the EpiAssembler, a new set of overlapping, conserved and immunogenic HIV-1 peptides were engineered creating extended "immunogenic consensus" sequences. Each overlapping 9-mer of the 20-23 amino acid long immunogenic consensus peptides was conserved in a large number (range 893-2254) of individual HIV-1 strains, although the novel peptides were not representative of any single strain of HIV. We synthesized nine representative peptides. T helper cell responses to the peptides were evaluated by ELISpot (gamma-interferon) assay, using peripheral blood monocytes (PBMC) obtained from 34 healthy long term non-progressor (LT) or moderate-progressor (MP) donors (median years infected = 8.88, median CD4 T cells = 595, median VL = 1044). Nine peptides were tested, of which eight were confirmed in ELISpot assays using PBMC from the LT/MP subjects. These epitopes were ranked by Conservation and EpiMatrix score 1, 2, 3, 5, 7, 11, and 14 out of the set of 9 original peptides. Five of these peptides were selected for inclusion in an epitope-driven cross-clade HIV-1 vaccine (the GAIA vaccine). These data confirm the utility of bioinformatics tools to select and construct novel "immunogenic consensus sequence" T cell epitopes for a globally relevant vaccine against HIV.

[1]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[2]  D. Montefiori,et al.  Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques , 1994, Journal of virology.

[3]  A. McMichael,et al.  DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. , 1998, Vaccine.

[4]  J. Altman,et al.  An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. , 2001, AIDS research and human retroviruses.

[5]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[6]  John L. Sullivan,et al.  Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection , 1995 .

[7]  H. Hoag.  Mixed results win HIV vaccine a guarded response , 2003, Nature.

[8]  J. Schmitz,et al.  Simian Immunodeficiency Virus (SIV) gag DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection , 2000, Journal of Virology.

[9]  A. D. De Groot,et al.  Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.

[10]  A. Trkola,et al.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.

[11]  M. Robert-Guroff,et al.  CD8 T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees. , 2000, AIDS.

[12]  J. S. Sullivan,et al.  Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.

[13]  Todd M. Allen,et al.  Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.

[14]  J. Lieberman,et al.  Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes. , 1996, Immunology letters.

[15]  M. Washabaugh,et al.  Memory T cells and vaccines. , 2003, Vaccine.

[16]  R. Zinkernagel,et al.  The discovery of MHC restriction. , 1997, Immunology today.

[17]  B. Graham.  Clinical trials of HIV vaccines. , 2002, Annual review of medicine.

[18]  J. Berzofsky,et al.  Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope. , 1991, The Journal of infectious diseases.

[19]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[20]  B. Moss,et al.  Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV , 2000, Journal of Virology.

[21]  Julie McMurry,et al.  Immuno‐informatics: Mining genomes for vaccine components , 2002, Immunology and cell biology.

[22]  N. Nagelkerke,et al.  Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya , 1996, The Lancet.

[23]  Søren Brunak,et al.  Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation , 2002, Journal of Virology.

[24]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[25]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[26]  Philip R. Johnson,et al.  Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles , 2000, Journal of Virology.

[27]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[28]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[29]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[30]  J. Berzofsky,et al.  ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. , 1995, The Journal of clinical investigation.

[31]  J. Whitton,et al.  A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen , 1997, Journal of virology.

[32]  J. Whitton,et al.  A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge , 1993, Journal of virology.

[33]  E. Rosenberg,et al.  Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection , 2001, The Journal of experimental medicine.

[34]  M. Mccarthy.  HIV vaccine fails in phase 3 trial , 2003, The Lancet.

[35]  D J Hu,et al.  The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. , 1996, JAMA.

[36]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[37]  M. Low.  Pituitary adenomas in man and mouse: oncogenic potential of a truncated fibroblast growth factor receptor 4. , 2002, The Journal of clinical investigation.

[38]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[39]  Michael A. Gonzalez,et al.  From genome to vaccine: in silico predictions, ex vivo verification. , 2001, Vaccine.

[40]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[41]  J. Berzofsky,et al.  HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. , 1994, JAMA.

[42]  Larry R. Smith,et al.  Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine1 , 2001, The Journal of Immunology.

[43]  Kendall A. Smith.  The HIV vaccine saga , 2003, Medical immunology.

[44]  D. Ho,et al.  The HIV-1 Vaccine Race , 2002, Cell.

[45]  M. Robb,et al.  Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. , 1999, The Journal of infectious diseases.

[46]  David L. Woodland,et al.  The Majority of Immunogenic Epitopes Generate CD4+ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues1 , 2002, The Journal of Immunology.

[47]  Todd M. Allen,et al.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef , 1999, Nature Medicine.

[48]  Judy Lieberman,et al.  Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. , 2003, Vaccine.

[49]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[50]  Kristin Beaudry,et al.  Viral Escape from Dominant Simian Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes in DNA-Vaccinated Rhesus Monkeys , 2003, Journal of Virology.

[51]  Jon Cohen.  AIDS Vaccine Trial Produces Disappointment and Confusion , 2003, Science.

[52]  Martin A. Nowak,et al.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.

[53]  Anne S De Groot,et al.  Bioinformatics tools for identifying class I-restricted epitopes. , 2003, Methods.

[54]  M. Robert-Guroff,et al.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge , 1997, Journal of virology.

[55]  J. Lang,et al.  Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons. , 2001, Immunology letters.

[56]  G. Learn,et al.  Maintaining the integrity of human immunodeficiency virus sequence databases , 1996, Journal of virology.

[57]  S. Rowland-Jones,et al.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women , 1995, Nature Medicine.

[58]  S. Buus,et al.  Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. , 1999, Vaccine.

[59]  R. Phillips,et al.  Escape of human immunodeficiency virus from immune control. , 1997, Annual review of immunology.

[60]  D. Chargelegue,et al.  Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. , 1999, The Journal of general virology.

[61]  E. Paoletti,et al.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria , 1996, Infection and immunity.